Effect of adding vildagliptin to insulin in haemodialysed patients with type 2 diabetes : The VILDDIAL study, a randomized, multicentre, prospective study
© 2020 John Wiley & Sons Ltd..
AIM: To evaluate the effect of adding the dipeptidyl-peptidase-4 inhibitor vildagliptin to insulin on the glycaemic control of patients with type 2 diabetes undergoing haemodialysis.
METHODS: Overall, 65 insulin-treated patients with type 2 diabetes undergoing haemodialysis (HbA1c: 7.3% ± 1.1%; age: 70.5 ± 8.5 years) were randomized (1:1) either to receive vildagliptin 50 mg/day in addition to insulin (vildagliptin-insulin group) or to pursue their usual insulin regimen (insulin-only group). Continuous glucose monitoring (CGM) was performed for 48 ± 6 hours at baseline and at week 12. The primary study endpoint was change from baseline in mean interstitial glucose using CGM. The secondary endpoints included other CGM variables and glucose control markers.
RESULTS: After 12 weeks, a greater reduction in mean CGM glucose from baseline was observed in the vildagliptin-insulin group compared with the insulin-only group, although the between-treatment difference was not statistically significant (mean difference [CI 95%]: -0.96 mmol/L [-2.09; 0.18] vs. -0.29 mmol/L [-1.29; 0.76], P = 0.32). However, a significant decrease from baseline in HbA1c, glycated albumin and insulin daily doses was observed in the vildagliptin-insulin group versus the insulin-only group (-0.6% [-1.19; -0.1], P < 0.01), in the vildagliptin-insulin group versus no change in the insulin-only group (-130.6 μmol/L [-271; 10.7] vs. +36.2 μmol/L [-164.4; 236.9], P = 0.04 and - 5.9 IU/day [-1.8; 7.1] vs. +1.1 IU/day [-14.5; 16.6], P = 0.01, respectively). There was no significant difference in the percentage of time spent in hypoglycaemia using CGM, occurrence of severe hypoglycaemia or number of adverse events.
CONCLUSION: In this study, vildagliptin added to insulin improved glycaemic control with an associated insulin-sparing effect in patients with type 2 diabetes undergoing haemodialysis and was well tolerated.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Diabetes, obesity & metabolism - 22(2020), 6 vom: 08. Juni, Seite 978-987 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Munch, Marion [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 31.05.2021 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/dom.13988 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM306427605 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM306427605 | ||
| 003 | DE-627 | ||
| 005 | 20231225123338.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/dom.13988 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1021.xml |
| 035 | |a (DE-627)NLM306427605 | ||
| 035 | |a (NLM)32048396 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Munch, Marion |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effect of adding vildagliptin to insulin in haemodialysed patients with type 2 diabetes |b The VILDDIAL study, a randomized, multicentre, prospective study |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.05.2021 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2020 John Wiley & Sons Ltd. | ||
| 520 | |a AIM: To evaluate the effect of adding the dipeptidyl-peptidase-4 inhibitor vildagliptin to insulin on the glycaemic control of patients with type 2 diabetes undergoing haemodialysis | ||
| 520 | |a METHODS: Overall, 65 insulin-treated patients with type 2 diabetes undergoing haemodialysis (HbA1c: 7.3% ± 1.1%; age: 70.5 ± 8.5 years) were randomized (1:1) either to receive vildagliptin 50 mg/day in addition to insulin (vildagliptin-insulin group) or to pursue their usual insulin regimen (insulin-only group). Continuous glucose monitoring (CGM) was performed for 48 ± 6 hours at baseline and at week 12. The primary study endpoint was change from baseline in mean interstitial glucose using CGM. The secondary endpoints included other CGM variables and glucose control markers | ||
| 520 | |a RESULTS: After 12 weeks, a greater reduction in mean CGM glucose from baseline was observed in the vildagliptin-insulin group compared with the insulin-only group, although the between-treatment difference was not statistically significant (mean difference [CI 95%]: -0.96 mmol/L [-2.09; 0.18] vs. -0.29 mmol/L [-1.29; 0.76], P = 0.32). However, a significant decrease from baseline in HbA1c, glycated albumin and insulin daily doses was observed in the vildagliptin-insulin group versus the insulin-only group (-0.6% [-1.19; -0.1], P < 0.01), in the vildagliptin-insulin group versus no change in the insulin-only group (-130.6 μmol/L [-271; 10.7] vs. +36.2 μmol/L [-164.4; 236.9], P = 0.04 and - 5.9 IU/day [-1.8; 7.1] vs. +1.1 IU/day [-14.5; 16.6], P = 0.01, respectively). There was no significant difference in the percentage of time spent in hypoglycaemia using CGM, occurrence of severe hypoglycaemia or number of adverse events | ||
| 520 | |a CONCLUSION: In this study, vildagliptin added to insulin improved glycaemic control with an associated insulin-sparing effect in patients with type 2 diabetes undergoing haemodialysis and was well tolerated | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a continuous glucose monitoring | |
| 650 | 4 | |a haemodialysis | |
| 650 | 4 | |a insulin treatment | |
| 650 | 4 | |a type 2 diabetes | |
| 650 | 4 | |a vildagliptin | |
| 650 | 7 | |a Blood Glucose |2 NLM | |
| 650 | 7 | |a Glycated Hemoglobin A |2 NLM | |
| 650 | 7 | |a Hypoglycemic Agents |2 NLM | |
| 650 | 7 | |a Insulin |2 NLM | |
| 650 | 7 | |a Nitriles |2 NLM | |
| 650 | 7 | |a Pyrrolidines |2 NLM | |
| 650 | 7 | |a Vildagliptin |2 NLM | |
| 650 | 7 | |a I6B4B2U96P |2 NLM | |
| 650 | 7 | |a Adamantane |2 NLM | |
| 650 | 7 | |a PJY633525U |2 NLM | |
| 700 | 1 | |a Meyer, Laurent |e verfasserin |4 aut | |
| 700 | 1 | |a Hannedouche, Thierry |e verfasserin |4 aut | |
| 700 | 1 | |a Kunz, Kristian |e verfasserin |4 aut | |
| 700 | 1 | |a Alenabi, Farideh |e verfasserin |4 aut | |
| 700 | 1 | |a Winiszewski, Patrice |e verfasserin |4 aut | |
| 700 | 1 | |a Baltzinger, Philippe |e verfasserin |4 aut | |
| 700 | 1 | |a Smagala, Agnès |e verfasserin |4 aut | |
| 700 | 1 | |a Klein, Alexandre |e verfasserin |4 aut | |
| 700 | 1 | |a Dorey, François |e verfasserin |4 aut | |
| 700 | 1 | |a Fleury, Dominique |e verfasserin |4 aut | |
| 700 | 1 | |a Verier-Mine, Odile |e verfasserin |4 aut | |
| 700 | 1 | |a Guerci, Bruno |e verfasserin |4 aut | |
| 700 | 1 | |a Cridlig, Joëlle |e verfasserin |4 aut | |
| 700 | 1 | |a Borot, Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a Ducloux, Didier |e verfasserin |4 aut | |
| 700 | 1 | |a Meyer, Nicolas |e verfasserin |4 aut | |
| 700 | 1 | |a Hadjadj, Samy |e verfasserin |4 aut | |
| 700 | 1 | |a Chantrel, François |e verfasserin |4 aut | |
| 700 | 1 | |a Kessler, Laurence |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Diabetes, obesity & metabolism |d 1999 |g 22(2020), 6 vom: 08. Juni, Seite 978-987 |w (DE-627)NLM111220432 |x 1463-1326 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2020 |g number:6 |g day:08 |g month:06 |g pages:978-987 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/dom.13988 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2020 |e 6 |b 08 |c 06 |h 978-987 | ||